论文部分内容阅读
为探讨N-ras基因突变在骨髓增生异常综合征(MDS)病变过程中的意义,采用多聚酶链反应-单链构象多态(PCR-SSCP)分析法检测20例MDS患者N-ras癌基因,其中5例出现N-ras基因突变,占25%,其中3例随访半年内转变为急性髓细胞白血病(AML),且对化疗不敏感。提示N-ras基因突变可促进MDS恶性克隆过度增生。初步表明N-ras基因突变的检测可作为一种分子生物学标志,用于监测MDS向AML转化
To investigate the significance of N-ras gene mutation in the pathogenesis of myelodysplastic syndrome (MDS), we used polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) assay to detect N-ras oncogene in 20 patients with MDS. Among them, 5 cases showed N-ras gene mutation, accounting for 25%, of which 3 cases were converted to acute myeloid leukemia (AML) within six months of follow-up and were insensitive to chemotherapy. It suggests that N-ras gene mutation can promote the hyperplasia of MDS malignant clones. It has been initially shown that detection of N-ras mutations can be used as a molecular biomarker to monitor the conversion of MDS to AML.